Author:
Matsumoto Tetsuya,Hanaki Hideaki,Kimura Toshimi,Nemoto Manabu,Higashihara Masaaki,Yokota Hiroyuki,Oda Shigeto,Akiyama Nobu,Miyao Naoki,Yoshida Minoru,Yukioka Tetsuo,Soma Kazui,Ohyashiki Kazuma,Suzuki Yukio,Arai Takao,Ikegami Keiichi,Ichiwata Toshio,Otsuka Yoshihito,Kobayashi Masahiro,Totsuka Kyoichi,Sunakawa Keisuke
Subject
Infectious Diseases,Pharmacology (medical),Microbiology (medical)
Reference18 articles.
1. Evaluation of once-daily administration of arbekacin. Experimental study and determination of pharmacokinetic properties in man;Totsuka;Jpn J Antibiot,1994
2. New antimicrobial agent series XL: arbekacin;Niijima;Jpn J Antibiot,1991
3. Meiji Seika Pharma Co., Ltd. Package insert of Habekacin® Injection, version 7, 2011.
4. Study of clinical significance of PK/PD (pharmacokinetic/pharmacodynamic) parameters after administering arbekacin to patients with pulmonary methicillin-resistant Staphylococcus aureus infection;Tanikaze;Jpn J Chemother,2004
5. An open clinical study of arbekacin 200 mg q.d. in patients infected with methicillin-resistant Staphylococcus aureus (MRSA)—a clinical pharmacology study;Aikawa;Jpn J Chemother,2008